Romel Somwar

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells
    Romel Somwar
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Biomol Screen 14:1176-84. 2009
  2. ncbi Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS Med 4:e294. 2007
  3. ncbi Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
    Romel Somwar
    High Throughput Screening Core Facility, and Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA or
    Proc Natl Acad Sci U S A 108:16375-80. 2011
  4. ncbi Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Marissa N Balak
    Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 12:6494-501. 2006
  5. ncbi Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
    Juliann Chmielecki
    Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
    Sci Transl Med 3:90ra59. 2011
  6. ncbi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e73. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells
    Romel Somwar
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Biomol Screen 14:1176-84. 2009
    ..Identification of the targets of LCS-1 and other growth inhibitors found in this screen may help to develop new agents for the treatment of lung adenocarcinomas, including those driven by mutant EGFR and KRAS...
  2. ncbi Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS Med 4:e294. 2007
    ..We sought to improve understanding of this process in order to provide insight into mechanisms of sensitivity and/or resistance to tyrosine kinase inhibitors and to uncover new targets for therapy...
  3. ncbi Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
    Romel Somwar
    High Throughput Screening Core Facility, and Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA or
    Proc Natl Acad Sci U S A 108:16375-80. 2011
    ..These results suggest that SOD1 is an LCS-1-binding protein that may act in concert with mutant proteins, such as EGFR and KRAS, to promote cell growth, providing a therapeutic target for compounds like LCS-1...
  4. ncbi Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Marissa N Balak
    Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 12:6494-501. 2006
    ..Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anatomic site and mode of binding to the kinase target...
  5. ncbi Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
    Juliann Chmielecki
    Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
    Sci Transl Med 3:90ra59. 2011
    ..This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance...
  6. ncbi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e73. 2005
    ..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance...